Ranbaxy launches cevimeline hydrochloride capsules in US market
Ranbaxy Pharmaceuticals on Tuesday launched the authorised generic cevimeline hydrochloride 30 mg capsules in the US market under an agreement with Daiichi Sankyo.
Drug major Ranbaxy Laboratories on Wednesday said it has withdrawn 27 drugs from the US market due to commercial reasons.